Karyopharm sees Q3 revenue $42-$44M, consensus $39.56M

Based on preliminary financial information, the Company expects Q3 total revenue, which includes license and royalty revenue from partners, to be in the range of $42M-$44M and U.S. XPOVIO net product revenue to be approximately $32M. Prior to the receipt of approximately $36 million of gross proceeds from the financing transactions, the Company expects to report that it had cash, cash equivalents, restricted cash and investments as of September 30 of approximately $46M. The financial information presented in this press release reflects the Company’s estimates with respect to total revenue, U.S. XPOVIO net product revenue and its cash balance and is based on currently available information, which is preliminary.